Collaborations - Alnylam Pharmaceuticals supports external organizations in joint projects that advance education, ongoing research, and responses to community needs to improve patient health.
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (review) | At least 45 days before the activity or program starts (submission)
Funding Amounts: No award amount specified; approved funding may be less than requested
Summary: Supports joint projects with external organizations that advance education, ongoing research, and community needs to improve patient health.
Key Information: Organizations or entities only; individuals cannot apply for or receive funding.
Alnylam Pharmaceuticals supports collaborations through its Grants and Giving Office. These are activities or projects undertaken jointly with one or more external organizations, with each party contributing particular expertise or services. The program supports innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically relevant, performance-based education and improve patient health.
Projects should enable education, address unmet needs, elevate the standard of care, focus on ongoing research, or respond to other relevant community needs. Alnylam’s stated disease areas of interest are transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1).